245 related articles for article (PubMed ID: 16642541)
21. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
22. The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis.
Unterecker S; Proft F; Riederer P; Lauer M; Deckert J; Pfuhlmann B
Ther Drug Monit; 2014 Apr; 36(2):269-72. PubMed ID: 24365982
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Reis M; Lundmark J; Björk H; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P
J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923
[TBL] [Abstract][Full Text] [Related]
25. Venlafaxine serum levels and CYP2D6 genotype.
Veefkind AH; Haffmans PM; Hoencamp E
Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
[TBL] [Abstract][Full Text] [Related]
26. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
27. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
28. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
[TBL] [Abstract][Full Text] [Related]
29. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
30. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Preskorn SH
J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
[TBL] [Abstract][Full Text] [Related]
31. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
[TBL] [Abstract][Full Text] [Related]
32. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
33. Desvenlafaxine: another "me too" drug?
Sopko MA; Ehret MJ; Grgas M
Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
[TBL] [Abstract][Full Text] [Related]
34. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression.
Hsiao CC
Psychoneuroendocrinology; 2006 Aug; 31(7):839-46. PubMed ID: 16716529
[TBL] [Abstract][Full Text] [Related]
35. Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms.
Alexandrino-Silva C; Nadalini Mauá FH; de Andrade AG; de Toledo Ferraz Alves TC
J Psychopharmacol; 2008 Mar; 22(2):214-6. PubMed ID: 18208934
[TBL] [Abstract][Full Text] [Related]
36. Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
Gex-Fabry M; Balant-Gorgia AE; Balant LP; Rudaz S; Veuthey JL; Bertschy G
Eur J Clin Pharmacol; 2004 Feb; 59(12):883-91. PubMed ID: 14704834
[TBL] [Abstract][Full Text] [Related]
37. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
38. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity.
Wijnen PA; Limantoro I; Drent M; Bekers O; Kuijpers PM; Koek GH
Ann Clin Biochem; 2009 Nov; 46(Pt 6):527-30. PubMed ID: 19822698
[TBL] [Abstract][Full Text] [Related]
39. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
40. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
